foxo4-dri peptide senolytic study The disordered p53 transactivation domain is the target of FOXO4 and the compound Buy FOXO4-DRI (Proxofim) - Senolytic
Buy FOXO4 DRI (Proxofim) Senolytic Peptide For Cellular Renewal Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine FOXO4 DRI Dosing: 1mg Senolytic Protocol (2026) Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv
Pay in 4 interest-free payments of $6.67 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12



